




PERMEACIÓ TRANSDÈRMICA D'UNA SÈRIE DE BENZODIAZEPINES



Màrius Duran i Hortolà



Unitat de biofarmàcia i fàrmaco-cinètica
Facultat de farmàcia
Universitat de Barcelona



8. BIBLIOGRAFIA

Consideracions generals

Per a referenciar tots els treballs, llibres, revistes electròniques, programes informàtics, etc., s'ha pres com a model de referència l'estil de Vancouver 2000, que estableix els requisits uniformes dels manuscrits enviats a revistes biomèdiques. El Comitè Internacional de Revistes Mèdiques es va constituir formalment a Vancouver l'any 1978 i per aquest motiu va ser conegut com a Grup Vancouver.

El Comitè Internacional de Directores de Revistes Mèdiques (CIDRM) ha elaborat cinc edicions dels requisits uniformes. La cinquena edició (1997) va suposar un esforç per reorganitzar i redactar amb claredat el contingut de la quarta edició i centrar els interessos sobre drets, privacitat, descripció dels mètodes i altres matèries. Donada la riquesa del document crec que es bo, també, referenciar-lo (Vancouver, 2000). Donat el desconeixement de l'existència d'una adaptació a la llengua catalana d'aquestes normes, m'he guiat pel format indicat per a la llengua castellana. A tall d'exemple s'exposen a continuació algunes de les referències més significatives que es poden trobar en el present treball.

“Artículos de Revistas”

(1) Artículo estándar

Autor/es. Título del artículo. Abreviatura* internacional de la revista año; volumen (número)**: página inicial-final del artículo.

Díez Jarilla JL, Cienfuegos Vázquez M, Suárez Salvador E. Ruidos adventicios respiratorios: factores de confusión. *Med Clin (Barc)* 1997; 109 (16): 632-634.

*Las abreviaturas internacionales pueden consultarse en "[List of Journals Indexed in Index Medicus](#)", las españolas en el catálogo de revistas del [Instituto Carlos III](#).

** El número es optativo si la revista dispone de nº de volumen.

Se mencionan seis primeros autores seguidos de la abreviatura *et al.* (Nota: *National Library of Medicine* (NLM), incluye hasta 25 autores; cuando su número es mayor cita los primeros 24, luego el último autor y después *et al.*).

Más de seis autores

Martín Cantera C, Córdoba García R, Jane Julio C, Nebot Adell M, Galán Herrera S, Aliaga M et. al. *Med Clin (Barc)* 1997; 109 (19): 744-748.

(2) Autor Corporativo

Grupo de Trabajo de la SEPAR. Normativa sobre el manejo de la hepatisis amenazante. Arch Bronconeumol 1997; 33: 31-40.

“Libros y otras Monografías”

Nota: la anterior edición del estilo Vancouver añadía, de manera errónea, una coma en lugar de punto y coma entre el editor y la fecha.

(16) Autores individuales

Autor/es. Título del libro. Edición. Lugar de publicación: Editorial; año.

Nota: La primera edición no es necesario consignarla. La edición siempre se pone en números arábigos y abreviatura: 2ª ed.- 2nd ed. Si la obra está compuesta por más de un volumen, debemos citarlo a continuación del título del libro Vol: 3

Jimenez C, Riaño D, Moreno E, Jabbour N. Avances en trasplante de órganos abdominales. Madrid: Cuadecon; 1997.

(17) Editor(es) Compilador(es)

Gallo Vallejo FJ, León López FJ, Martínez-Cañavate López-Montes J, Tonío Duñantez J. Editores. Manual del Residente de Medicina Familiar y Comunitaria. 2ªed.. Madrid: SEMFYC; 1997.

(18) Organización como autor y editor

Ministerio de Sanidad y Consumo. Plan de Salud 1995. Madrid: Ministerio de Sanidad y Consumo; 1995.

(19) Capítulo de libro

Autor/es del capítulo. Título del capítulo. En: Director/Recopilador del libro. Título del libro. Edición. Lugar de publicación: Editorial; año. p. página inicial-final del capítulo.

Nota: el anterior estilo Vancouver tenía un punto y coma en lugar de una "p" para la paginación.

Buti Ferret M. Hepatitis vírica aguda. En: Rodés Teixidor J, Guardia Massó J dir. *Medicina Interna*. Barcelona: Masson; 1997. p. 1520-1535.

(20) Actas de conferencias

Kimura J, Shibasaki H, editors. Recent advances in clinical neurophysiology.



Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology; 1995 Oct 15-19; Kyoto, Japón. Amsterdam: Elsevier; 1996.

(21) Ponencia presentada a una conferència

Autor/es de la Comunicació/Ponencia. Títol de la Comunicació/Ponencia. En: Títol oficial del Congrés. Lloc de Publicació: Editorial; any. pàgina inicial-final de la comunicació/ponencia.

Nota: És freqüent que la data i ciutat de celebració formi part del títol del Congrés. Aquesta mateixa estructura s'aplica a Jornades, Simposis, Reunions Científiques, etc.

Peiró S. Avaluació comparativa de l'eficiència sanitària i qualitat hospitalària mitjançant perfils de pràctica mèdica. En: Menen R, Ortun V editors. Política i gestió sanitària: la agenda explícita. Seminari Elements per a una agenda en política i gestió sanitària; València 25-26 de abril de 1996. Barcelona: SG editors; 1996. p. 63-78

(22) Informe científic o tècnic

Tesis Doctoral

Autor. Títol de la tesi. [Tesis Doctoral] . Lloc de edició: Editorial; any.

Muñoz García J. Estudi transversal dels factors de risc cardiovascular en població infantil del mitjà rural gallego. [Tesis doctoral] . Santiago: Servei de Publicacions i Intercanvi Científic, Universitat de Santiago; 1996.

Artícle de revista en format electrònic

Autor. Títol. Nom de la revista abreujat [tipus de suport] any [data d'accés]; volum (número): pàgines o indicador d'extensió. Disponible en:

Transmission of Hepatitis C Virus infection associated infusion therapy for hemophilia. MMWR [en línia] 1997 July 4 [data d'accés 11 de gener de 2001]; 46 (26). URL disponible en:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/00048303.htm>

(34) Monografia en format electrònic

Título. [Tipo de soporte] . Editores o productores. Edición. Versión. Lugar de publicación: Editorial; año.

Duane`s Ophthalmology en CD-ROM User Guide. [monografía en CD-ROM]. Tasman W, Jaeger E editor. version 2.0. Hagenstown: Lippincolt-Raven; 1997.

(35) Archivo informático

Autor.Título.[Tipo de soporte]. Versión. Lugar: Editorial; año.

Hemodinámics III: the ups and downs of hemodynamics [programa de ordenador]. Versión 2.2. Orlando (FL): Computerized Educational Systems; 1993.

CLASSIFICACIÓ PER AUTOR

Abraham MH, Chadha HS, Martins F, Mitchell RC, Bradbury MW, Gratton JA. *A review of the correlation and prediction of transport properties by an LFER method: physicochemical properties, brain penetration and skin.* Pest Sci 1999; 55: 78-88.

Abraham MH, Martins F, Mitchell RC. *Algorithms for skin permeability using hydrogen bond descriptors: the problem of steroids.* J Pharm Pharmacol 1997; 49: 858-865.

Abraham MH. *Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes.* Chem Soc Rev 1993; 22: 73 - 83.

Agache P. *Epiderme, poil, glandes sébacées et sudoripares. A: Prunieras M. Précis de dermatologie.* Paris : Masson. 1981; p. 1 - 36.

Alsina MA, Mestres C, Rabanal F, Busquets MA, Reig F. *Miscibility of HBV Peptides and Dipalmitoylphosphatidylcoline in Monolayers.* Langmuir (Am Chem Soc) 1993; 9 (4): 1129 - 1133.

American Society of Health-System Pharmacist. *AHFS Drug 2001 Information.* Bethesda: American Soc Health-System Pharmac, Inc 2001.

Anjo DM, Feldmann RJ, Maibach HI. *Methods for predicting percutaneous penetration in man. A: Mauvais Jarvis. Percutaneous penetration of steroids.* New-York: Academic Press. 1980; p. 31-51.

Arendt R, Greenblatt J, Liebisch C, Lun D, Paul M. *Psychopharmacology.* Berlin: Springer-Verlag 1987; 93: 72.

Atkins PW. *Physical Chemistry.* Oxford: University Press: New York (USA) 1998.



Baker RW, Lonsdale HK. *Controlled release: mechanism and rates*. A: Tanquary AC, Lacey RE. *Controlled release of biologically active agents*. New-York: Plenum Press 1974; p. 18.

Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP. *Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment*. Arch Gen Psychiat 1998; 45: 413- 422.

Balter MB, Levine J, Manheimer DI. *Cross-national study of the extend of anti-anxiety*. N Eng J Med 1974; 290: 769-774.

Bamio-Nuez A, Artalejo-Ortega B, Franquesa-Graner R, del Pozo Carrascosa A, Faulí Trillo C. *Benzodiacepinas: estudio comparativo de la estabilidad*. Cir Far 1990; 306: 97-110.

Barratt MD. *Quantitative structure-activity relationships for skin permeability*. Tox in vitro 1995; 9: 27-37.

Barry BW. *Optimizing percutaneous absorption*. A: Bronaugh RL, Maibach HI. *Percutaneous absorption*. New York: Marcel Dekker. 1989; p. 531-555.

Barry BW. *Action of skin penetration enhancers: The lipid protein partitioning theory*. Int J Cosmet Sci 1988; 10: 281-293.

Behl Cr, Harper NJ, Pei JY, Kumar S, Metha D, Char H et al. *A general method for assessing skin permeation enhancement mechanisms and optimization*. A: Hsieh DS. *Drug Permeation Enhancement. Theory and Application*. New York: Marcel Dekker, Inc. 1994; p. 107- 141.

Bellantuono C, Reggi V, Tognoni G, Garattini S. *Benzodiazepines: Clinical Pharmacology and Therapeutic Use*. Drugs 1980; 19: 195- 219.

Berner B, Cooper ER. *Asymptotic solution for non steady-state diffusion through oil-water multilaminates*. J Membrane Sci 1983; 14: 139-145.

Berner B, Cooper ER. *Application of diffusion theory to the relationship between partition coefficient and biological response*. J Membrane Sci 1984; 73: 102-106.

Berner B, Cooper ER. *Pharmacokinetics of skin penetration*. A: Kydoneius AF, Berner B. *Transdermal drug delivery of drugs*. Florida: CRC 1987; 2: p. 42-46.

Birdi KS. *Lipid and polimer monolayers at liquid interfaces*. Plenum Press: New York 1989.

Boix A. *Estudio de penetración transdérmica del Alprazolam* . [Tesis doctoral]. Universitat de Barcelona; 1998.

Bonina FP, Carelli V, Di Colo G, Montenegro L, Nannipieri E. *Vehicle effects on in vitro skin permeation of and estratum corneum affinity for model drugs caffeine and testosterone*. Int J Pharm 1993; 100: 41 - 47.

Brain KR. *Adopting an appropriate analytical approach. A: Prediction of Percutaneous Penetration-Methods, Measurements, Modelling.* Londres: IBC Technical Services Ltd. 1991; p. 137-147.

Bressolle F, Bromet-Petit M, Audran M. *Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics.* J Chromatog B 1996; 686: 3-10.

Brialy-Auclair F, Besnard M, Dupont Ch, Wepierre J. *Drug distribut in skin after percutaneous absorp. Importance of blood flow, physico-chemical propert and absorp rate bipedic dors Hairl rat.* Fund Clin Pharmacol 1990; 4: 437.

Brockman H. *Lipid monolayers: why use half a membrane to characterize protein-membrane interactions?.* Curr Opin Struct Biol 1999; 9: 438.

Bronaugh RL, Maibach HI. *Percutaneous Absorption.* New York: Marcel Dekker, INC 1989.

Bucks DA, Maibach HI, GuY RH. *Occlusion does not uniformly enhance penetration in vivo. A: Bronaugh RL, Maibach HI .Editors. Percutaneous absorption.* New York, Bâle: Marcel Dekker 1989; p. 77-93.

Cajal Y, Alsina MA, Reig F, Rodriguez L, Mestres C, Haro I. *Interaction of a Multiple Antigenic Peptide of Hepatitis A Virus with Monolayers and Bilayers of Acidic, Basic, and Zwitterionic Phospholipids.* Colloid Polym Sci 1998; 198: 78 - 86.

Calpena A, Blanes C, Domènech J. *A comparative study in vitro of transdermal absorption of antiemetics.* J Pharm Sci 1994; 83 (1): 29-33.

Camacho MA, Torres AI, Gil ME, Obregón M i Ruiz V. *Validation protocol of analytical methods for finished pharmaceutical products.* S.T.P Pharma Pratiques 1993; 3 (3): 197 - 202.

Chien YW. *Transdermal therapeutic systems. A: Robinson JR, Lee VHL. Controlled Drug Delivery, Fundamentals and applications.* New York and Basel: Marcel Dekker. 1988.

Chien YW *et al.* *Transdermal iontophoretic delivery of therapeutic peptides/proteins in insulin.* Annals of New-York Acad Sci 1988; 507: 32-51.

Consejo General Col Farmaceuticos. *Catalogo de especialidades farmacéuticas 2001.* Madrid: Consejo General Col Farmaceuticos. Febrer 2001.

Cordero JA. *Estudios de permeación transdérmica y actividad tópica de una serie de antiinflamatorios no esteroides.* [Tesis doctoral]. Universitat de Barcelona; 1998.

Cordero JA, Alarcon L, Escribano E, Obach R, Domenech J. *A comparative study of transdermal penetration of a series of nonsteroidal antiinflammatory drugs.* J Pharm Sci 1997; 86 (4): 503-508.



Cormier M, Ledger PW, Marty JP, Amkraut A. *The in vitro cutaneous biotransformation of propranolol*. J Invest Dermatol 1991; 97: 447-452.

Corroler M, Didry JR, Siou G, Wepierre J. *Sebaceous accumulation of linoleic acid following topical application in the hairless rat and its mathematical treatment*. A: Shroot B, Schaefer H. *Skin pharmacokinetics*. Basel: Karger 1987; p. 111-120.

Costa P, Ferreira DC, Morgado R, Sousa-Lobo JM. *Design and evaluation of a Lorazepam Transdermal System*. Drug Dev and Ind Phar 1997; 23 (10): 939 - 944.

Crank J. *The mathematics of diffusion*. 2ed. New-York: Oxford University Press 1975.

Cronin MTD, Dearden JC, Moss GP, Murray-Dickson G. *Investigation of the mechanism of flux across human skin "in vitro" by quantitative structure-permeability relationship*. Eur J Phar Sci 1999; 7: 325-330.

Cronin MTD, Dearden JC, Gupta R, Moss GP. *An investigation of the mechanism of flux across polydimethylsiloxane membranes by use of quantitative structure-permeability relationships*. J Pharm Pharmacol 1998; 50: 143-152.

Dearden JC. *Partitioning and Lipophilicity in Quantitative Structure Activity Relationships*. Environmental Health Perspectives 1985; 61: 203-228.

Dearden JC, Bradburne SJA, Cronin MTD, Solanki P. *Physical Significance of Molecular Connectivity*. Proceedings III International Workshop on QSAR Tox 1988; 43-50.

Dearden JC, Bresnen GM. *The Measurement of Partition Coefficients*. Quant Struct-Act Relat 1988; 7: 133-144.

Departament de Sanitat i Seguretat Social. *Pla de Salut 1999-2001*. Barcelona: Generalitat de Catalunya 1999; p. 157.

Departamento técnico del Consejo General de Colegios Oficiales de Farmacéuticos. *Catálogo de especialidades farmacéuticas*. Madrid: Consejo General Colegios Oficiales de Farmacéuticos 2001.

Diez I. *Aportación a la absorción percutánea de una sèrie de dihidropiridinas*. [Tesis doctoral]. Universitat de Barcelona; 1992.

Du Plessis J, Pugh W, Judefeind A, Hadgraft J. *The effect of hydrogen bonding on diffusion across model membranes: consideration of the number of H-bonding groups*. Eur J Pharm Sci 2001; 13 (2): 135 - 141.

Dugard PH. *Skin permeability theory in relation to measurements of percutaneous absorption*. A: Marzulli FN, Maibach HI. *Toxicology Dermatology*. New York: Hemisphere. 1981; p. 91-129.

Duran M. *Aportació a l'estudi de permeació transdèrmica de Benzodiazepines*. [Tesina]. Facultat de Farmàcia. Universitat de Barcelona; 1994.

Earll M. *A guide to Log P and pKa measurements and their use*. Cchem MRSC[en línia] 1999[data accés març 2002] URL disponible a: <http://www.raell.demon.co.uk/chem/logp/>.

El Tayar N, Tsai RS, Testa B, Carrupt PA, Hansch C, Leo A. *Percutaneous penetration of drug : a quantitative structure.permeability relationship study*. J Pharm Sci 1991; 80: 744-749.

Elias PM. *Epidermal lipids, membrane and keratinisation*. J Invest Dermatol 1981; 20: 1-19.

Elias PM, Friend DS. *Permeability barriers and pathways in mammalians epidermis*. J Cell Biol 1974; 63: 93-98.

European Centre for Ecotoxicology and Toxicology of Chemicals. *Monograph: Percutaneous Absorption*. Brussels: ECETOC 1993; 20.

FDA: U.S. Department of Health and Human Services Food and Drug Administration . *Bioanalytical Method Validation*. Guidance for Industry 2001; 4-10.

Feldman RJ, Maibach HI. *Regional variation in percutaneous penetration of C-cortisol in Man*. J Invest Dermatol 1967; 48: 181-183.

Feldman RJ, Maibach HI. *Systemic absorption of pesticides through the skin of man. A: Occupational exposure to pesticides. Report to the Federal Working Group on pest management from the task group on occupational exposure to pesticides, Appendix B*. 1974; 120-127.

Feldman RJ, Maibach HI. *Penetration of C14-hidro cortisone through normal skin. The effect of stripping and occlusion*. Arch Dermatol 1965; 91: 181-183.

Florence AT, Atwood D. *Physicochemical Principles of Pharmacy 2nd edition*. Houndmills : MacMillan 1991.

Flórez J; Armijo JA, Mediavilla A. *Farmacología humana (3ª ed.)*. Barcelona: Masson S.A: 1997.

Flynn GL. *Physicochemical determinants of skin absorption. In principles of route-to-route extrapolation for risk assessment*. New York: TR Gerrety and CJ Henry, Elsevier 1990; p. 93-127.

Flynn GL. *Mechanism of percutaneous absorption from physical evidence. A: Bronaugh RL, Maibach HI. Percutaneous absorption*. New York: Marcel Dekker. 1989; p. 27-51.

Flynn GL, Stewart B. *Percutaneous drug penetration: choosing candidates for transdermal development*. Drug Develop Res 1988; 13: 169-185.

Foye W, Lemke T, Williams DA. *Principles of Medicinal Chemistry (4th edition)*. Baltimore : Williams&Wilkins. 1995.



Franz J, Toho K, Shah KR, Kydonieus A. *Transdermal delivery. A: Kydonieus. Treatise on controlled delivery*. New-York, Basel and Hon-Kong: Marcel Dekker 1987.

Freedberg I *et al.* *Fitzpatrick's Dermatology in General Medicine*. (5th ed). New York: McGraw Hill 1999; 1: p. 3.

Gao S, Singh J. *In vitro percutaneous absorption enhancement of a lipophilic drug tamoxifen by terpenes*. J Cont Rel 1998; 51: 193 - 199.

Gingauz A. *Introduction to Medicinal Chemistry*. Wiley-VCH 1997.

Gobas APC, Lahittete JM, Garofalo G, Shiu WY. *A novel method for measuring membrane-water partition coefficients of hydrophobic organic chemicals: Comparison 1-octanol-water partitioning*. J Phar Sci 1988; 77: 265-272.

Golden GM, Guzek DB, Mckie JE, Potts RO. *The role of stratum corneum lipid fluidity in transdermal drug flux*. J Pharm Sci 1986; 76: 25-31.

Goodman, Gilman. *Las bases farmacológicas de la terapéutica*. 9ena ed. México D.F: McGraw Hill Interamericana Editores S.A. 1996; 2: p. 385 -.

Grafourian T, Fooladi S. *The effect structural QSAR parameters on skin permeation*. Int J Pharm 2001; 217: 1-11.

Graham JM, Higgins JA. *Membrane Analysis*. BIOS Scientific Publishers Ltd. Oxford (UK) 1997.

Greenblatt J, Harmatz JS, Shader RI. *Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly*. Clin Pharmacokinet 1991; 21 (3): 165- 177.

Guy RH, Hadgraft J. *Interpretation and prediction of de kinetics of transdermal drug delivery: estradiol, hyoscine and timolol*. Int J Pharm 1986; 32: 159-163.

Guy RH, Hadgraft J, Maibach HI. *A pharmacokinetic model for percutaneous absorption*. . Int J Pharm 1982; 11 (2): 193-203.

Hadgraft J. *Skin, the final frontier*. Int J Pharm 2001; 224: 1 - 18.

Hadgraft J, Guy R. *Drugs and the pharmaceutical sciences: Transdermal drug delivery*. New York: Marcel Dekker, Inc 1989; 35.

Hadgraft J, Guy RH. Editores. *Transdermal Drug Delivery, 1989. Development Issues and Research initiatives*. New York and Basel: Marcel Dekker. 1989.

Hansch C. *Comprehensive Medicinal Chemistry (Cumulative Subject index&Drug Compendium)*. Oxford: Pergamon Press 1990; 6: p. 262-394-401-441-629-678-779.

Hansch C, Leo A. *Substituent Constants for Correlation Analysis in Chemistry and Biology*. New York: Wiley. 1979.

Harris DR *et al.* *Percutaneous absorption and the surface area of occluded skin.* Brit J Derm 1974; 1: 27-31.

Higuchi T. *Rate of release of medicaments from ointment bases containing Drug in suspension.* J Pharm Sci 1961; 86: 1616-1626.

Hueber F, Wepierre J, Schaefer. *Role of transepidermal and transfollicular routes in percutaneous absorption of hidro cortisone and testostérone: In vivo study in the hairless rat.* Skin Pharmacol 1992; 5: 99-107.

Idson B. *Percutaneous absorption.* J Pharm Sci 1975; 64 (6): 901 - 921.

Illel B, Schafer H. *Transfollicular percutaneous absorption.* Acta Derm Venereol 1988; 68: 427-457.

Kamlet MJ, Abboud JL, Abraham MH, Taft RW. *Linear solvation energy relationships. 23. A comprehensive collection of the solvatochromic parameters, pi, alpha and beta, and some methods for simplifying the generalized solvatochromic equation.* J Org Chem 1983; 48: 2877 - 2887.

Kao J. *The influence of metabolism on percutaneous absorption. A: Bronaugh RL, Maibach HI. Percutaneous absorption.* New York: Marcel Dekker. 1989; p. 259-282.

Kao J *et al.* *In vitro percutaneous absorption in mouse skin : influence of skin appendages. .* Toxicol Appl Pharmacol 1988; 94: 93-103.

Kao J *et al.* *Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man: An in vitro study with benzo(a)pyrene and testosterone.* Toxicol Appl Pharmacol 1985; 81: 502-516.

Kao J, Hall J. *Skin absorption and cutaneous first-pass metabolism of topical steroids : In vitro studies with mouse skin in organ culture.* J Pharmacol Exp Ther 1987; 241: 482-487.

Kasting GB, Smith RL, Cooper ER. *Effect of lipid solubility and molecular size on percutaneous absorption.* Pharmacol Skin Paris: Karger 1987; 138-152.

Katayama K, Nagai T. *Limonene and related compounds as potential skin penetration promoters.* Drug Dev Ind Pharm 1994; 20 (4): 677-684.

Kligman AM. *A biological brief on percutaneous absorption.* Drug Dev Indust Pharm 1983; 9: 521-560.

Laihanen N, Yliruusi J. *Physical stability of alprazolam crystal modifications I and II.* STP Pharma Sciences 1996; 6 (4): 264- 271.

Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E, Elias PM . *Human stratum corneum lipids: characterization and regional variations.* J Lipid Res 1983; 24 (2): 120- 130.



- Langmuir I. *J Am Chem Soc* 1917; 39: 1848-1906.
- Leahy DE *et al.* *QSAR: rational approaches to the design of bioactive compounds*. New York: Elsevier 1991; p. 75-82.
- Leo A, Hansch C and Elkins D. *Partition coefficients and their uses*. *Chemical Reviews* 1971; 71 (6): 525- 554.
- Levine NI. *Fisicoquímica 4ª ed.* McGraw-Hill: Madrid 1996; 1: p. 386.
- Li Wan Po A. *Statistics for pharmacists*. Oxford: Blackwell Science Ltd. 1998.
- Lien EJ, Gao H. *QSAR analysis of skin permeability of various drugs in man as compared to in vivo and in vitro studies in rodents*. *Pharm Res* 1995; 4: 583-587.
- Liu P, Nightingale JAS, Kurihara-Bergstrom T. *Variation of human skin permeation in vitro: Ionic vs neutral compounds*. *Int J Pharm* 1993; 90: 171 - 176.
- Livingstone DJ. *The characterization of chemical structures using molecular properties. A survey*. *Journal of Chemical Information and Computer Scie* 2000; 40: 195-209.
- Loftsson T, Guomundsdóttir H *et al.* *Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray*. *Int J Pharm* 2001; 212: 29-40.
- López-Castellano A, Cortell-Ivars C, López-Carballo G, Herráez-Dominguez M. *The influence of Span 20 on stratum corneum lipids in Langmuir Monolayers: comparison with Azone*. *Int J Pharm* 2000; 203 (1-2): 245-253.
- Ma F, Lau CE. *Determination of midazolam and its metabolites in serum microsamples by HPLC and its application to pharmacokinetics in rats*. *J Chromatogr B* 1996; 682: 109-113.
- Magee PS. *Some novel approaches to modelling transdermal penetration and reactivity with epidermal proteins. In comparative QSAR*. London: Taylor&Francis, J. Devillers 1998; p. 137-168.
- Maget-Dana R. *The monolayer technique: a potent tool for studying the interfacial properties of antimicrobial and membrane-lytic peptides and their interaction with lipid monolayers*. *Biochim Biophys Acta* 1999; 109: 1462.
- Maibach HI, Feldman RJ, Milby TH, Serat WF. *Regional variation in percutaneous penetration in man*. *Arch Environ Health* 1971; 23: 208-211.
- Marty JP, Bucks DA, Maibach HI. *Percutaneous penetration as a method of delivery to muscle and other tissue A: Bronaugh RL, Maibach HI. Percutaneous absorption*. New York: Marcel Dekker. 1989; p. 435-442.
- Marty JP, Dervault Am. *Thérapeutique dermatologique*. Paris: Médecine-Sciences Flammarion. 1991; p. 649-663.

Maryadele JO, Smith A, Heckelman PE, Obenchaim jr. JR, Gallipean JA, D'Arecca MA et al. Editores. *The Merck Index. 13th ed.* Whitehouse Station, NJ: Merck&CO., Inc 2001.

Medicom. *Vademecum Internacional (42^a ed)* . Madrid : Medicom S.A. 2001.

Meilan WH, Howard PH, Boethling RS. *Improved method for estimating water solubility from octanol/water partition coefficient.* Environ Toxicol Chem 1996; 15: 100-106.

Meilan WM , Howard PH. *Atom/fragment contribution method for estimating octanol-water partition coefficients.* J Pharm Sci 1995; 84: 83-92.

Mestres C, Alsina MA, Busquets MA, Haro I, Reig F. *Interaction of Enrofloxacin with Phospholipid Mono- and Bilayers.* Langmuir (Am Chem Soc) 1994; 10 (3): 767 -772.

Michaels AS, Chandrasekaran SK, Shaw JE,. *Drug permeation through human skin, theory and in vitro experimental measurement.* A I Ch E J 1975; 21 (5): 985-996.

Ministerio de Sanidad y Consumo. *Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 1995.* Inf Ter Sist Nac Salud 1996; 20: 114- 116.

Ministerio de Sanidad y Consumo. *Grupos terapeuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 2000.* Inf Ter Sist Nac Salud 2001; 25 (3).

Ministerio de Sanidad y Consumo. *Grupos terapeuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 1999.* Inf Ter Sist Nac Salud 2000; 24 (3).

Mitragotri S, Blankschtein D, Langer R. *An explanation for the variation of the sonophoretic transdermal transport enhancement from drug to drug.* J Pharm Sci 1997; 86 (10): 1190-1192.

Moffat AC. *Clarke's Isolation and Identification of drugs (2nd edition).* London: Pharmaceutical Press 1986.

Noonan P, Wester RC. *Cutaneous metabolism of xenobiotics. A: Bronaugh RL, Maibach HI. Percutaneous absorption.* New York: Marcel Dekker. 1989; 53-75.

Núñez M. *Catálogo de especialidades Farmacéuticas 1999.* Cons. Gen. Colegios Oficiales Farmacéuticos 1999; p. 1474 - 1519 -1533.

Obata Y, Takayama K, Maitani Y, Madrida Y, Nagai T. *Effect of pretreatment of skin with cyclic monoterpenes on permeation of Diclofenac in hairless rat.* Biol Pharm Bull 1993; 16 (3): 312 - 314.

Oliveros S, Hernández C, Baca E. *Uso racional de benzodiazepinas.* Inf Ter Sist Nac Salud 1997; 21 (5): 114-126.



O'Neil, Smith A, Heckelman PE, Obenchaim jr. JR, Gallipean JA, D'Arecca MA, Budavari S. *The Merck Index. 13th edition.* Whitehouse Station NJ: Merck&CO., Inc. 2001.

Organisation for Economic Co-operation and Development. *Test Guideline : Skin Absorption : In Vitro Method .* Paris : OECD 2000; p. 428.

O'Sullivan GH *et al.* *Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.* Br J Psychiat 1994; 165: 79-86.

Pacifici GM, Cuoci L, Guarneri M, Fornaro P, Arcidiacono G, Capelli N, Moggi G, Placidi GF. *Placental transfer of Pinazepam and its metabolite N-desmethyldiazepam in women at term.* Eur J Clin Pharmacol 1984; 27: 307- 310.

Patel H, Cronin M . *Determination of the optimal physico-chemical parameters to use QSAR-approach to predict skin permeation rate.* Liverpool John Moores University 2001.

Pauld R, Macspadden SK. *Diffusional release of a solute from a polymer matrix.* J Membrane Sci 1976; 1: 33-48.

Potts RD. *Stratum corneum hydratation: experimental techniques and interpretation of results.* J Soc Cosmet Chem 1986; 37: 19-33.

Potts RO , Guy RH. *Predicting skin permeability.* Pharm Res 1992; 9 (5): 663-669.

Potts RO, Guy RH. *A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity.* Pharm Res 1995; 12: 1628 - 1633.

Poulin P , Krishnan K. *Molecular structure-based prediction of human abdominal skin permeability coefficients for several organics compounds.* J Tox Env Health 2001; Part A 62: 143-159.

Pugh EJ, Hadgraft J. *Ab initio prediction of human skin permeability coefficients.* Int J Pharm 1994; 103: 163 - 178.

Pugh WJ, Degim IT, Hadgraft J. *Epidermal permeability-penetrant structure relationships.4. QSAR of permeant diffusion across human st. corneum in terms of mol. w.,H-bond e .* Int J Pharm 2000; 197: 203-211.

Pugh WJ, Hadgraft J. *Ab initio prediction of human skin permeability coefficients.* Inter J Pharm 1994; 103: 163 - 178.

Pugh WJ, Roberts MS, Hadgraft J. *Epidermal permeability-penetrant structure relationships: 3. The effect of hydrogen bonding interactions and molecular size on diffusion across the stratum corneum.* Int J Pharm 1996; 138: 149-165.

Puglia C, Bonina F, Trapani G, Franco M, Ricci M. *Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations.* Int J Pharm 2001; 228: 79-87.

- Ranade V, Hollinger. *Drug delivery systems*. Boca Raton: CRC Press, Inc 1996; p. 177-208.
- Ray MP. *Analytical Methods Validation Guidelines News. USA. 1994. 1-3.*
- Reig F, Busquets MA, Haro I, Rabanal F, Alsina MA. *Interaction of opiate molecules with lipid monolayers and liposomes*. J Pharm Sci 1992; 81 (6): 546-550.
- Repetto R, Repetto M. *Habitual, Toxic, and Lethal Concentrations of 103 Drugs of Abuse in Humans*. Clin Toxicol 1997; 35 (1): 1- 9.
- Rickels K, Fox IL, Greenblatt DJ. *Clorazepate and lorazepam: clinical improvement and rebound anxiety*. Am J Psychiatry 1988; 145: 312-317.
- Robbins L, Regier DA. *Psychiatric disorder in America*. Nueva York: Free Press 1991.
- Roberts MS, Anissimov YG, Gonsalvez RA. *Mathematical models in percutaneous absorption. (3ª edició) A: Bronaugh RL, Maibach HI. Percutaneous absorption*. New York-Basel: Marcel Dekker, Inc. 1999; 97: p. 3-55.
- Roberts MS, Walters KA. *The relationship between structure and barrier function of skin. A: Roberts MS, Walters KA, editors. Dermal absorption and toxicity assesment*. New York: Marcel Dekker. 1998.
- Roberts MS. *Percutaneous absorption of phenolic compounds*. Ph. D. Tesis, University of Sidney. Australia. 1976.
- Robinson K, Rutherford MG, Smith RN. *A sensitive benzodiazepine radioimmunoassay of broad specificity*. J Pharm Pharmacol 1980; 32: 773- 777.
- Rougier A, Lotte C. *In vivo relationship between percutaneous absorption and transepidermal water loss. A: Bronaugh RC, Maibach HI. Editors. Percutaneous absorption*. New York-Bâle: Marcel Dekker 1989; p. 415-434.
- San L, Tato J, Torrens M, Castillo C, Farré M, Camí J. *Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification*. Drug Alcohol Dependend 1993; 32 (3): 281-286.
- Skelly JJ, Shah VP, Maibach HI, Guy RH, Wester RC, Flynn G, Yacobi A. *FDA and AAPS Report on Workshop on principles and practice In vitro percutaneous studies: relevance to bioavailability and bioequivalence*. Pharm Res 1987; 4(3): 265-267.
- Schaefer H, Zesch A, Stüggen G. *Penetration, permeation and absorption of triamcinolone acetonide in normal and psoriatic skin*. Arch Dermatol Res 1977; 258: 241 - 249.
- Scheuplein RJ. *Mechanism of percutaneous absorption: I. Routes of penetration and the influence of solubility*. J Invest Dermatol 1965; 45: 334-346.



Scheuplein RJ. *Mechanism of percutaneous absorption: Transcient diffusion and the relative importance of various routes of skin penetration*. J Invest Dermatol 1967; 48: 78-89.

Scheuplein RJ. *Properties of skin as a membrane. A: Montagna W. Advances in biology of skin, vol 12, Pharmacology and the skin*. New York: Meredith Corporation 1972; 10.

Scheuplein RJ et al. *Permeability of the skin. A: Amer Physiol Soc. Handbook of physiology, Sec 9, reaction to environmental Agents*. Whashington DC: DH Lee 1977; p. 299-232.

Scheuplein RJ, Blank IH, Brauner GJ, Mac Farlane DJ. *Percutaneous absorption of steroids*. J Invest Dermatol 1969; 52: 63-70.

Scheuplein RJ, Blank IH. *Permeability of the skin*. Phisiol Rev 1971; 51: 707 - 747.

Scheuplein RJ, Brounaugh RL. *Percutaneous absorption "Biochemistry and physiology of the skin*. New York: Oxford University Press 1983; 2: p. 1255-1295.

Schwarz G, Taylor SE. *Polymorphism and interactions of a viral fusion peptide in a compressed lipid monolayer*. Bioph J 1999; 76: 3167.

Schwarz JS, Weisspapier MR, Friedman DI. *Enhanced transdermal delivery of Diazepam by submicron emulsion (SME) creams*. Pharm Res 1995; 12 (5): 687- 692.

Schweizer E, Rickels K, Uhlenhuth EH. *Issues in the long-term treatment of anxiety disorders. Psychopharmacology: The fourth generation of progress*. New York: Raven Press 1995.

Schweizer E, Rickels K, Weiss S, Zavodnick S. *Maintenance drug treatment for panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine*. Arch Gen Psychiat 1993; 50: 51- 60.

Seiller M, Martini MC. *Formes pharmaceutiques pour application locale*. Paris: Technique&Documentation 1996.

Shah VP, Midha KK, Dighe S, Mcgilveray IJ, Skelly JP, Yacobi A et al. *Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies*. Journal Pharmaceutical Sciences 1992; 81 (3): 309- 312.

Sheehan CV, Ballenger J, Jacobsen G. *Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms*. Arch Gen Psychiat 1980; 37: 51- 59.

Sloan JB, Soltani K. *Iontophoresis in dermatology*. J Am Acad Dermatol 1986; 15: 671-684.

Snyder LR, Kirkland JJ. *Introduction to Modern Liquid Chromatography (2nd edition)* . New York : John Wiley & Sons, Inc. 1979.

SOFTWARE. *Numerical inversion of Laplace transforms*. Salt Lake city: Micromath Scientific software, Inc. 1991.

SOFTWARE. *SigmaPlot for Windows Version 5.00*. SPSS Inc. 1999.

SOFTWARE. *DATMSA. Data file generation for multivariate statistical analysis v5.0*. CompuDrug LTD. 1985.

SOFTWARE. *ANALYSIS SLREGR v5.0. Stepwise linear regression analysis*. CompuDrug LTD. 1985.

SOFTWARE. *NCSS 97. Visual Components* 1997.

SOFTWARE. *RECTESTX*. Unitat de Biofarmàcia i Farmacocinètica 1990.

SOFTWARE. *CS Chem 3D Pro*. CambridgeSoft Corporation: USA 1997.

SOFTWARE ACD. *ACD / ChemSketch v5.11*. Toronto 2001.

SOFTWARE USEPA. *DERWIN v 1.42*. Washington, DC: U.S. Environmental Protection Ag. 2000.

SOFTWARE. Fernández L. *ARVOMOL*. Madrid: Dep. Química i Bioquímica de ETSIM de la UPM .

Sospedra P, Espina M, Alsina MA, Haro I, Mestres C. *Study at the Air/Water Interface of a Hepatitis A N-Acetylated and C-Aminated Synthetic Peptide (AcVP3(110-121)-NH₂)*. *J Colloid Interface Sci* 2001; 244: 79-86.

Sun L, Liu. *Transdermal drug delivery by phonophoresis: Basics, mechanisms and techniques of application. A : Hsieh SD. Drug permeation enhancement*. New York: Marcel Dekker. 1994; p. 303 - 321.

Surinchak JS, Malinowski JA, Wilson DR, Maibach HI. *Skin wound healing determined by water loss*. *J Surg Res* 1985; 38: 258-262.

Szabo G. *The regional frequency and distribution of hair follicles in human skin. A : Montagna W, Ellis RA. The biology of hair growth*. New-York: Academic Press. 1958; p. 33-38.

Tam L K. *Incorporation of a synthetic mitochondrial signal peptide into charged and uncharged phospholipid monolayers*. *Biochemistry* 1986; 25: 7470-7476.

Tas J, Feige Y. *Penetration of radioiodide through human skin*. *J Invest Dermatol* 1958; 30: 1993-197.

Taylor PJ. *Hydrophobic Properties of Drugs in Comprehensive Medicinal Chemistry*. Oxford: Pergamon Press, Ramsden CA 1990; 4: p. 241-294.



Touitou E, Meidan VH, Horwitz E. *Methods for quantitative determination of drug localized in the skin*. J Cont Rel 1998; 56: 7 - 21.

USP XXIII - NF XVIII. *Guideline for submitting samples and Analytical Data for Methods Validation*. Ed. U.S. Pharmacopeial Convention Inc. Rockville, U.S.A 1995; 1225.

Vaes WHJ, Ramos EU, Verhaar HJM, Cramer CJ, Hermens JLM. *Understanding and estimating membrane-water partition coefficients: approaches to derive quantitative structure property relationships*. Chem Res Tox 1998; 11: 847-854.

Vancouver 2000, CIDRM. www.fisterra.com/recursos_web/mbe/vancouver.htm. 2002.

Verger R, De Hass DH. *Enzyme reactions in a membrane model. 1. A new technique to study reactions in monolayers*. Chem Phys Lipids 1973; 10: 127-136.

Wang P-H, Lien EJ. *Effects of Different Buffer Species on Partition Coefficients of Drugs Used in Quantitative Structure-Activity Relationships*. J Pharm Sci 1980; 69: 662-668.

Wepierre J. *L'imperméabilité de la peau de la souris à l'égard du perhydrosqualene tritié*. Ann Pharm Fr 1967; 25: 515 - 521.

Wepierre J, Doucet O, Marty JP. *Percutaneous absorption of drugs in vitro: role of transepidermal and transfollicular routes*. A: Scott RC, Hadgraft J, Guy RH. *Prediction of percutaneous penetration*. London: IBC Technical Services. 1990; p. 129-139.

Wepierre J, Marty JO. *Percutaneous absorption and lipid in elderly skin*. J Appl Cosmetol 1988; 6: 79-92.

Wertz PW, Berg Bvd. *The physical, chemical and functional properties of lipids in the skin and other biological barriers*. Chem Phys Lipids 1998; 91 (2): 85 - 96.

Wester RC, Maibach HI. *In vivo animals for percutaneous absorption*. A: Bronaugh RL, Maibach HI. *Percutaneous absorption*. New York: Marcel Dekker. 1989; p. 221-238.

Wester RC, Maibach HI. *Cutaneous pharmacokinetics: ten steps in percutaneous absorption*. Drug Metab Rev 1983; 14: 169-205.

Williams AC, Barry BW. *The use of terpenes as skin penetration enhancers*. A: Scott RC, Guy RH, Hadgraft J, editors. *Prediction of percutaneous penetration. Methods, measurements, modelling*. London: IBC Technical Services Ltd 1990; p. 224 - 230.

Williams AC, Cornwell PA, Barry BW. *On the non-Gaussian distribution of human skin permeabilities*. Int J Pharm 1992; 86: 69-77.

Williams BW, Scotto AW, Stubbs CD. *Biochemistry*. 1990; 29: 324-328.

Williams VC, Varnado GC, Nwangwu PU. *Perspectives on the Clinical Pharmacology of Benzodiazepines*. Drugs of today 1985; 21 (2): 75- 96.

Wong O, Mckeown. *Substituent effects on partition coefficients of barbituric acids*. J Pharm Sci 1988; 77: 926-.

Woods JH , Katz JL , Winger G. *Benzodiazepine: use, abuse and consequences*. Pharmacol Rev 1992; 44: 155 - 186.

www.medynet.com. *Benzodiazepine pharmacokinetics*. Micromedex Inc. 1998.

Yu CD, Fox JL, Ho NFH, Higuchi WI. *Physical model evaluation of topical prodrug delivery-simultaneous transport bioconversion of vidarabine- 5'-valerate*. J Pharm Sci 1979; 68 (11): 1341-1352.

Zesch A, Schaefer H. *Penetration of radioactive hydrocortisone in human skin from various ointment bases. II: in vivo experiments*. Arch Dermatol Forsch 1975; 252: 245 - 256.